Skip to main content
Fig. 4 | Molecular Neurodegeneration

Fig. 4

From: Pim1 inhibition as a novel therapeutic strategy for Alzheimer’s disease

Fig. 4

Pim1i decreases Aβ pathology. a The graph shows the phosphorylated levels of PRAS40 levels after 28 days of treatment, measured by sandwich ELISA. The Pim1 inhibitor significantly reduced the pPRAS40 levels of both the 3xTg-AD and NonTg mice as evident by a significant effect of treatment (F(1, 42) = 36.593, p < 0.0001). b Representative microphotographs of brain sections from 3xTg-AD mice stained with an Aβ42 specific antibody (Millipore, catalog number AB5078P). d Quantitative analysis of Aβ42 immunoreactivity by unpaired t-test reveals that 3xTg-AD mice treated with Pim1i had significantly fewer plaques compared to 3xTg-AD mice treated with vehicle (t (8) = 8.419, p < 0.05). Error bars represent mean ± SEM

Back to article page